A Phase 1, Open-label Study to Evaluate SGN-35C in Adults With Advanced Malignancies
Categories (click each to see list of all clinical trials associated with that category): Lymphoma/CLL (ONC)
Current Status: Open
Phase: I (Cancer Control)
Principal Investigator: Vose, Julie
Contact Information:
Katie Bourret
kbourret@unmc.edu
Eligibility: https://clinicaltrials.gov/study/NCT06254495?term=NCT06254495&rank=1#participation-criteria
Summary
Primary
● To characterize the safety and tolerability of SGN-35C in subjects with relapsed/refractory (R/R) lymphomas
● To identify the maximum tolerated dose of SGN-35C
● To identify a recommended dose and schedule of SGN-35C
Secondary
● To characterize the immunogenicity of SGN-35C
● To characterize the pharmacokinetics (PK) of SGN-35C
● To assess the antitumor activity of SGN-35C
Exploratory
● To assess the relationship of CD30-expression with clinical response to SGN-35C
● To explore potential tissue and blood biomarkers associated with response, toxicity, and resistance to SGN-35C
● To assess the antitumor activity of SGN-35C (time-to-event based)